Immunovant (IMVT) Earnings Date, Estimates & Call Transcripts $15.80 -0.10 (-0.63%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$15.80 0.00 (0.00%) As of 05/2/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immunovant Earnings Summary Upcoming Q4 Earnings DateJun. 4Before Market OpensEstimatedConsensus EPS (Feb. 10) -$0.68 Actual EPS (Feb. 10) -$0.76 Missed By -$0.08 Immunovant posted Q3 2025 earnings on February 10, 2025, reporting an EPS of -$0.76, which missed the consensus estimate of -$0.68 by $0.08. With a trailing EPS of -$2.62, Immunovant's earnings are expected to decrease next year, from ($2.69) to ($3.08) per share. Q3 2025 Earnings ResourcesQ3 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)SEC FilingIMVT Upcoming EarningsImmunovant's next earnings date is estimated for Wednesday, June 4, 2025, based on past reporting schedules. Powered by Get Immunovant Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataIMVT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Immunovant Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.57-$0.41-$0.50Q2 20254-$0.62-$0.54-$0.59Q3 20254-$0.64-$0.54-$0.59Q4 20254-$0.75-$0.56-$0.65 FY 2025 15 -$2.58 -$2.05 -$2.32 Q1 20262-$0.82-$0.62-$0.72Q2 20262-$0.87-$0.64-$0.76Q3 20262-$0.86-$0.64-$0.75Q4 20262-$0.82-$0.67-$0.75 FY 2026 8 -$3.37 -$2.57 -$2.97 Q1 20271-$0.87-$0.87-$0.87Q2 20271-$0.89-$0.89-$0.89Q3 20271-$0.91-$0.91-$0.91 Immunovant Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 6/4/2025(Estimated)--------2/10/2025Q3 2025-$0.68-$0.76 -$0.08-$0.76--11/7/2024Q2 2025-$0.59-$0.74 -$0.15-$0.74--8/6/2024Q1 2025-$0.53-$0.60 -$0.07-$0.60--5/29/2024Q4 2024-$0.44-$0.52 -$0.08-$0.52--2/12/2024Q3 2024-$0.43-$0.36+$0.07-$0.36--11/9/2023Q2 2024-$0.45-$0.45--$0.45--8/10/2023Q1 2024-$0.44-$0.47 -$0.03-$0.37--5/22/2023Q4 2023-$0.41-$0.46 -$0.05-$0.46-- Immunovant Earnings - Frequently Asked Questions When is Immunovant's earnings date? Immunovant has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, June 4th, 2025 based off last year's report dates. Learn more on IMVT's earnings history. Did Immunovant beat their earnings estimates last quarter? In the previous quarter, Immunovant (NASDAQ:IMVT) missed the analysts' consensus estimate of ($0.68) by $0.08 with a reported earnings per share (EPS) of ($0.76). Learn more on analysts' earnings estimate vs. IMVT's actual earnings. How can I view Immunovant's earnings report? Immunovant's earnings report can be found in their filing with the SEC. View SEC filing How much profit does Immunovant generate each year? Immunovant (NASDAQ:IMVT) has a recorded net income of -$259.34 million. IMVT has generated -$2.62 earnings per share over the last four quarters. What is Immunovant's EPS forecast for next year? Immunovant's earnings are expected to decrease from ($2.69) per share to ($3.08) per share in the next year. More Earnings Resources from MarketBeat Related Companies Ascendis Pharma A/S Earnings Viatris Earnings Qiagen Earnings Roivant Sciences Earnings Revolution Medicines Earnings Lantheus Earnings BridgeBio Pharma Earnings TG Therapeutics Earnings Legend Biotech Earnings Sarepta Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback PlanMicrosoft Crushes Earnings, What’s Next for MSFT Stock?Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay AwayAMD Stock Signals Strong Buy Ahead of Earnings This page (NASDAQ:IMVT) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMVT Stock Free IMVT Stock Alerts